Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 60

Results For "US"

7104 News Found

Aparna Group forays into pharma business; Receives USFDA clearance for manufacturing unit
News | February 15, 2024

Aparna Group forays into pharma business; Receives USFDA clearance for manufacturing unit

The company is strongly committed to enhancing customer satisfaction and catering to the discerning needs of renowned pharmaceutical companies


UBE announces Phase I clinical trial for SSAO/VAP-1 licensed exclusively to Novo Nordisk
Diagnostic Center | February 15, 2024

UBE announces Phase I clinical trial for SSAO/VAP-1 licensed exclusively to Novo Nordisk

MASH is a chronic and progressive liver disease characterised by fat accumulation and inflammation in the liver,


Lupin launches Bromfenac Ophthalmic Solution, 0.075% in US
News | February 14, 2024

Lupin launches Bromfenac Ophthalmic Solution, 0.075% in US

Bromfenac Ophthalmic Solution 0.075% (RLD BromSite) had estimated annual sales of USD 15 million in the U.S.


Sun Pharma included in S&P Global Sustainability Yearbook 2024
Sustainability | February 13, 2024

Sun Pharma included in S&P Global Sustainability Yearbook 2024

This recognition attests to Sun Pharma’s commitment to incorporate Environmental, Social, and Governance (ESG) principles through focused initiatives across its businesses


Lord's Mark Industries files patent for bio-chemistry reagents; Targets revenue of Rs. 200 Cr
Diagnostic Center | February 13, 2024

Lord's Mark Industries files patent for bio-chemistry reagents; Targets revenue of Rs. 200 Cr

These re-agent and diagnostic test kits come with 99.7% accuracy


Zydus receives Tentative Approval from the USFDA for Dexamethasone Tablets USP, 1 mg
Drug Approval | February 10, 2024

Zydus receives Tentative Approval from the USFDA for Dexamethasone Tablets USP, 1 mg

Dexamethasone is used to treat conditions such as arthritis, blood/hormone disorders, allergic reactions


Zydus Lifesciences Q3 FY24 PAT up 26.8%
News | February 10, 2024

Zydus Lifesciences Q3 FY24 PAT up 26.8%

Zydus’s revenue growth was led by India and EU formulations businesses in addition to that in the emerging markets.


Biocon Biologics partners with Sandoz Australia for Biosimilars Trastuzumab and Bevacizumab
News | February 10, 2024

Biocon Biologics partners with Sandoz Australia for Biosimilars Trastuzumab and Bevacizumab

The agreement is effective from January 1, 2024 and commercialisation commenced on February 1, 2024


Growth of Ayush sector is bound to happen: Kotecha
Policy | February 09, 2024

Growth of Ayush sector is bound to happen: Kotecha

Ayush is expanding beyond wellness to therapeutic wellness


Qure.ai adds new FDA breakthrough device status for qSpot-TB
Digitisation | February 09, 2024

Qure.ai adds new FDA breakthrough device status for qSpot-TB

4 FDA clearances & 61 EU MDR CE tags achieved for AI in 18 months